21577-57-1

Basic information

• Product Name: 2-AMINO-4,6-DIMETHOXY-BENZOIC ACID
• Synonyms: 2-AMINO-4,6-DIMETHOXY-BENZOIC ACID
• CAS NO: 21577-57-1
• Molecular Formula: C₉H₁₁NO₄
• Molecular Weight: 197.18794
• Mol File: 21577-57-1.mol
• Article Data: 10

Chemical Properties

• Melting Point: 120-125 °C
• Boiling Point: 374.809 °C at 760 mmHg
• Flash Point: 180.478 °C
• Appearance: /
• Density: 1.295 g/cm³
• Vapor Pressure: 0mmHg at 25°C
• Refractive Index: 1.582
• Storage Temp.: Sealed in dry,Room Temperature
• PKA: 5.10±0.10(Predicted)
• CAS DataBase Reference: 2-AMINO-4,6-DIMETHOXY-BENZOIC ACID(CAS DataBase Reference)
• NIST Chemistry Reference: 2-AMINO-4,6-DIMETHOXY-BENZOIC ACID(21577-57-1)
• EPA Substance Registry System: 2-AMINO-4,6-DIMETHOXY-BENZOIC ACID(21577-57-1)

Safety Data

• Statements: 36
• Safety Statements: 26
• Hazardous Substances Data: 21577-57-1(Hazardous Substances Data)

Usage

Description

2-AMINO-4,6-DIMETHOXY-BENZOIC ACID is an organic compound characterized by its amino group at the 2nd position, and methoxy groups at the 4th and 6th positions on a benzoic acid backbone. It serves as a key intermediate in the synthesis of various pharmaceutical compounds due to its unique chemical structure and reactivity.

Uses

Used in Pharmaceutical Industry:
2-AMINO-4,6-DIMETHOXY-BENZOIC ACID is used as a key intermediate for the synthesis of N-(5-Chloro-1,3-benzodioxol-4-yl)-7-[2-(4-methylpiperazin-1-yl)ethoxy]-5-(tetrahydro-2H-pyran-4-yloxy)quinazolin-4-amine. 2-AMINO-4,6-DIMETHOXY-BENZOIC ACID is a highly selective, orally available, dual-specific c-Src/Abl kinase inhibitor, which has potential applications in the treatment of various cancers by targeting specific cellular pathways involved in tumor growth and progression.

InChI:InChI=1/C9H11NO4/c1-13-5-3-6(10)8(9(11)12)7(4-5)14-2/h3-4H,10H2,1-2H3,(H,11,12)

Upstream product

• 10272-07-8 3.5-dimethoxyaniline 
• 40891-33-6 3,5-dimethoxyaniline hydrochloride 
• 21544-81-0 4,6-dimethoxyindoline-2,3-dione 
• 890093-49-9 2-nitro-4,6-dimethoxybenzoic acid 

Downstream Products

• 379228-26-9 methyl 2-amino-4,6-dimethoxybenzoate 

Relevant articles and documents

Design, synthesis and biological evaluation of novel HDAC inhibitors with improved pharmacokinetic profile in breast cancer

The dysfunction of histone deacetylase (HDACs) is closely related to tumorigenesis and development, which has been emerged as an attractive drug design target for cancer therapy. In the present study, we designed and synthesized a series of novel HDAC inhibitors using a substituted quinazoline as the capping group and attaching 3, 5-dimethylbenyl as a potential metabolic site protector. 23g and 23h were demonstrated potent HDAC inhibitory activities and anti-proliferative effects against MDA-MB-231 cells. In addition, 23g and 23h both could significantly increase the acetylation level of intracellular proteins, especially in α-Tubulin and HSP90. 23g and 23h displayed a slight different anti-tumor mechanism, 23g mainly induced apoptosis while 23h induced obviously ER-Stress. Furthermore, 23g and 23h both induced autophagy and migration inhibition. In pharmacokinetics assay, 23g showed a significant improvement of pharmacokinetic profile for oral administration. Additionally, 23g presented more potent anti-proliferation and anti-migration activity than SAHA in zebrafish MDA-MB-231 cell line-derived xenograft model. Together, these results demonstrate that 23g is a novel oral HDAC inhibitor with a potential capacity of treating breast cancer.

Used for the prevention and treatment of cardiovascular diseases

The invention relates to compounds that can be used for adjusting the expression of apolipoprotein A-I (ApoA-I) and usage of the compounds in treating and preventing cardiovascular diseases and related diseases, including the disorder related to cholesterol or lipids such as atherosclerosis.

COMPOUNDS FOR THE PREVENTION AND TREATMENT OF CARDIOVASCULAR DISEASES

The present disclosure relates to compounds, which are useful for regulating the expression of apolipoprotei? A-I (ApoA-l), and their use for the treatment and prevention of cardiovascular disease and related disease states, including cholesterol- or lipid-related disorders, such as, for example, atherosclerosis.